middle.news
Cogstate lands five Phase 3 trials as FY27 backlog strengthens
8:25am on Monday 12th of October, 2026 AEDT
•
Healthcare Technology
Read Story
Cogstate lands five Phase 3 trials as FY27 backlog strengthens
8:25am on Monday 12th of October, 2026 AEDT
Key Points
US$25.1 million in 1Q27 sales contracts, up from US$21.4 million
Five Phase 3 bipolar or depression trials across two customers
Contracted revenue rises 41% year on year to US$143.7 million
FY27 contracted revenue reaches US$56.8 million
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Cogstate (ASX:CGS)
OPEN ARTICLE